泼尼松龙

  • 基本信息
  • 制备方法及用途
  • 物化性质
  • 安全信息
  • 毒理性
  • MSDS
  • 结构与计算化学
  • 上游产品
  • 下游产品
  • 表征图谱

泼尼松龙 基本信息

中文名称:
泼尼松龙 
中文别名:
泼尼松龙;
11Beta,17Alpha,21-三羟基孕甾-1,4-二烯-3,20-二酮;
11β,17α,21-三羟基孕甾-1,4-二烯-3,20-二酮;
孕甾-1,4-二烯-11β,17α,21-三醇-3,20-二酮;
1,4-Pregnadiene-11β,17α,21-triol-3,20-dione;
去氢氢化可的松 
英文名称:
prednisolone
英文别名:
prednisolone;
steran;
dicortol;
ulacort;
STEROLONE;
hydeltra;
eazolind;
predonin;
deltaf;
Prednisolone;
prednis;
solone 
CAS No.:
50-24-8
分 子 式:
C21H28O5
分 子 量:
360.45
精确分子量:
360.19400
PSA:
94.83000
MDL:
MFCD00003649
EINECS:
200-021-7
BRN:
1354103
InChI:
The Key: OIGNJSKKLXVSLS-YDAVOWJHSA-N
危险品标志:
harmfulxn
风险术语:
R22   
分子结构式:
SDS:
查看

泼尼松龙 制备方法及用途

制备方法

可用氢化可的松经消除(生物节杆菌脱氢)制得该品。

合成制备方法

可用氢化可的松经消除(生物节杆菌脱氢)制得该品。

用途简介

激素药。适用于类风湿关节炎、风湿热、红斑狼疮、皮肌炎、多发性骨髓瘤等。

用途

适用于类风湿关节炎、风湿热、红斑狼疮、皮肌炎、多发性骨髓瘤等,还可制取氢化泼尼松醋酸酯。

泼尼松龙 物化性质

外观与性状:
结晶固体
密度:
1.31 g/cm3
熔点:
240 °C (dec.)(lit.)
沸点:
570.6ºC at 760 mmHg
闪点:
313ºC
折射率:
100 ° (C=1, Dioxane)
存储条件/存储方法:

本品密封避光干燥保存。

其它信息:

1.       性状:白色吸湿性粉末,无臭,味苦

2.       密度(g/mL,25/4℃):未确定

3.       相对蒸汽密度(g/mL,空气=1):未确定

4.       熔点(ºC):240 °C (dec.)(lit.)

5.       沸点(ºC,常压):未确定

6.       沸点(ºC, 5.2 kPa):未确定

7.       折射率:100 ° (C=1, Dioxane)

8.       闪点(ºC):未确定

9.       比旋光度(º):未确定

10.    自燃点或引燃温度(ºC):未确定

11.    蒸气压(kPa,25 ºC):未确定

12.    饱和蒸气压(kPa,60 ºC):未确定

13.    燃烧热(KJ/mol):未确定

14.    临界温度(ºC):未确定

15.    临界压力(KPa):未确定

16.    油水(辛醇/水)分配系数的对数值:未确定

17.    爆炸上限(%,V/V):未确定

18.    爆炸下限(%,V/V):未确定

19.    溶解性:溶于乙醇、氯仿、丙醇、甲醇、二氧六环,微溶于水


 

泼尼松龙 安全信息

海关代码:
2937229000
WGK_Germany:
3
德国有关水污染物质的分类清单
危险类别码:
R22
安全说明:
S22
RTECS号:
TU4152000
危险标志:
Xn:Harmful

泼尼松龙 毒理性

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TU4152000
CHEMICAL NAME :
Pregna-1,4-diene-3,20-dione, 11-beta,17,21-trihydroxy-
CAS REGISTRY NUMBER :
50-24-8
BEILSTEIN REFERENCE NO. :
1354103
LAST UPDATED :
199703
DATA ITEMS CITED :
48
MOLECULAR FORMULA :
C21-H28-O5
MOLECULAR WEIGHT :
360.49
WISWESSER LINE NOTATION :
L E5 B666 OV AHTTT&J A1 CQ E1 FV1Q FQ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
9 mg/kg/2W-I
TOXIC EFFECTS :
Behavioral - toxic psychosis
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
14 mg/kg/13D-I
TOXIC EFFECTS :
Behavioral - toxic psychosis
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
2 gm/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
147 mg/kg
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
120 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
1680 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
65 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
>3500 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intravenous
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
180 mg/kg
TOXIC EFFECTS :
Details of toxic effects not reported other than lethal dose value
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
1702 mg/kg/13W-I
TOXIC EFFECTS :
Nutritional and Gross Metabolic - weight loss or decreased weight gain Related to Chronic Data - death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
105 mg/kg/6W-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - changes in sodium
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
182 mg/kg/13W-I
TOXIC EFFECTS :
Liver - changes in liver weight Endocrine - changes in adrenal weight Biochemical - Metabolism (Intermediary) - other proteins
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
56 mg/kg
SEX/DURATION :
female 1-40 week(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - Central Nervous System Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - other neonatal measures or effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
23 mg/kg
SEX/DURATION :
female 1-33 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetal death
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
25 mg/kg
SEX/DURATION :
female 1-35 week(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
250 mg/kg
SEX/DURATION :
female 5-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - extra-embryonic structures (e.g., placenta, umbilical cord)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
600 mg/kg
SEX/DURATION :
female 5-22 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - hepatobiliary system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
30 mg/kg
SEX/DURATION :
female 9-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
7500 ug/kg
SEX/DURATION :
female 9-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
200 mg/kg
SEX/DURATION :
female 14-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
DOSE :
900 mg/kg
SEX/DURATION :
female 10-15 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - blood and lymphatic systems (including spleen and marrow)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
DOSE :
1200 ug/kg
SEX/DURATION :
female 9-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - musculoskeletal system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
8 mg/kg
SEX/DURATION :
female 12-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - physical
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
100 mg/kg
SEX/DURATION :
female 11-14 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants) Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
120 mg/kg
SEX/DURATION :
female 7-12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - other effects to embryo Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
4 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral Reproductive - Effects on Newborn - physical
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
12 mg/kg
SEX/DURATION :
female 13-18 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Subcutaneous
DOSE :
4 mg/kg
SEX/DURATION :
female 12 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - behavioral
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
100 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - post-implantation mortality (e.g. dead and/or resorbed implants per total number of implants)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
330 mg/kg
SEX/DURATION :
female 10 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Ocular
DOSE :
6 mg/kg
SEX/DURATION :
female 10-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Ocular
DOSE :
60 mg/kg
SEX/DURATION :
female 10-13 day(s) after conception
TOXIC EFFECTS :
Reproductive - Specific Developmental Abnormalities - urogenital system
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
56 mg/kg
SEX/DURATION :
female 11 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Embryo or Fetus - fetotoxicity (except death, e.g., stunted fetus) Reproductive - Specific Developmental Abnormalities - craniofacial (including nose and tongue)
TYPE OF TEST :
DNA inhibition

MUTATION DATA

TYPE OF TEST :
Mutation in mammalian somatic cells
TEST SYSTEM :
Rodent - mouse Lymphocyte
DOSE/DURATION :
1450 umol/L
REFERENCE :
MUTAEX Mutagenesis. (Oxford Univ. Press, Pinkhill House, Southfield Road, Eynsham, Oxford OX8 1JJ, UK) V.1- 1986- Volume(issue)/page/year: 3,193,1988 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - 83542 No. of Facilities: 68 (estimated) No. of Industries: 1 No. of Occupations: 6 No. of Employees: 2770 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - 83542 No. of Facilities: 680 (estimated) No. of Industries: 2 No. of Occupations: 3 No. of Employees: 3293 (estimated) No. of Female Employees: 897 (estimated)

泼尼松龙 MSDS


Section 1. Chemical Product and Company Identification
    Prednisolone
    Common Name/
    Trade Name
    Prednisolone

Section 3. Hazards Identification
    Potential Acute Health Effects Slightly hazardous in case of skin contact (irritant, permeator), of eye contact (irritant), of ingestion, of inhalation.
    Potential Chronic Health        Slightly hazardous in case of skin contact (sensitizer).    
    Effects        CARCINOGENIC EFFECTS: Not available.    
    MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast.
    TERATOGENIC EFFECTS: Not available.
    DEVELOPMENTAL TOXICITY: Classified Reproductive system/toxin/female, Reproductive system/toxin/male
    [POSSIBLE].

Section 4. First Aid Measures
    Eye Contact        Check for and remove any contact lenses. In case of contact, immediately flush eyes with plenty of water for at    
    least 15 minutes. Cold water may be used. WARM water MUST be used. Get medical attention if irritation
    occurs.
    Skin Contact        Wash with soap and water. Cover the irritated skin with an emollient. Get medical attention if irritation develops.    
    Serious Skin Contact        Not available.    
    Inhalation        If inhaled, remove to fresh air. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get    
    medical attention.
    Serious Inhalation        Not available.    
    Ingestion
    Do NOT induce vomiting unless directed to do so by medical personnel. Never give anything by mouth to an
    unconscious person. If large quantities of this material are swallowed, call a physician immediately. Loosen tight
    clothing such as a collar, tie, belt or waistband.
    Serious Ingestion        Not available.    

Section 5. Fire and Explosion Data
    Flammability of the Product May be combustible at high temperature.
    Auto-Ignition Temperature Not available.
    Flash Points        Not available.    
    Flammable Limits        Not available.    
    Products of Combustion        These products are carbon oxides (CO, CO2).    
    Fire Hazards in Presence of Slightly flammable to flammable in presence of heat.
    Various Substances        Non-flammable in presence of shocks.    
    Explosion Hazards in Presence Risks of explosion of the product in presence of mechanical impact: Not available.
    of Various Substances        Risks of explosion of the product in presence of static discharge: Not available.    
    Fire Fighting Media        SMALL FIRE: Use DRY chemical powder.    
    and Instructions        LARGE FIRE: Use water spray, fog or foam. Do not use water jet.    
    Special Remarks on        Not available.    
    Fire Hazards
    Special Remarks on Explosion Not available.
    Hazards
    Prednisolone

Section 6. Accidental Release Measures
    Small Spill        Use appropriate tools to put the spilled solid in a convenient waste disposal container. Finish cleaning by    
    spreading water on the contaminated surface and dispose of according to local and regional authority
    requirements.
    Large Spill        Use a shovel to put the material into a convenient waste disposal container. Finish cleaning by spreading water    
    on the contaminated surface and allow to evacuate through the sanitary system.

Section 7. Handling and Storage
    Precautions        Keep away from heat. Keep away from sources of ignition. Ground all equipment containing material. Do not    
    ingest. Do not breathe dust. Wear suitable protective clothing. If ingested, seek medical advice immediately and
    show the container or the label.
    Storage        Keep container tightly closed. Keep container in a cool, well-ventilated area.    

Section 8. Exposure Controls/Personal Protection
    Engineering Controls        Use process enclosures, local exhaust ventilation, or other engineering controls to keep airborne levels below    
    recommended exposure limits. If user operations generate dust, fume or mist, use ventilation to keep exposure to
    airborne contaminants below the exposure limit.
    Personal Protection        Safety glasses. Lab coat. Dust respirator. Be sure to use an approved/certified respirator or equivalent. Gloves.    
    Personal Protection in Case of Splash goggles. Full suit. Dust respirator. Boots. Gloves. A self contained breathing apparatus should be used
    a Large Spill        to avoid inhalation of the product. Suggested protective clothing might not be sufficient; consult a specialist    
    BEFORE handling this product.
    Exposure Limits        Not available.    

Section 9. Physical and Chemical Properties
    Physical state and appearance Solid. (Solid crystalline powder.)        Odor        Odorless.    
    Not available.
    Taste
    Molecular Weight        360.45 g/mole    
    White. Off-white.
    Color
    pH (1% soln/water)        Not available.    
    Boiling Point        Not available.    
    Melting Point        235°C (455°F)    
    Critical Temperature        Not available.    
    Specific Gravity        Not available.    
    Not applicable.
    Vapor Pressure
    Vapor Density        Not available.    
    Not available.
    Volatility
    Odor Threshold        Not available.    
    Water/Oil Dist. Coeff.        Not available.    
    Ionicity (in Water)        Not available.    
    Dispersion Properties        See solubility in water, methanol, acetone.    
    Solubility        Soluble in acetone.    
    Partially soluble in methanol.
    Very slightly soluble in cold water.
    Prednisolone

Section 10. Stability and Reactivity Data
    The product is stable.
    Stability
    Instability Temperature        Not available.    
    Excess heat, moisture
    Conditions of Instability
    Not available.
    Incompatibility with various
    substances
    Corrosivity        Non-corrosive in presence of glass.    
    Special Remarks on        Avoid exposure to moisture    
    Reactivity
    Special Remarks on        Not available.    
    Corrosivity
    Polymerization        Will not occur.    

Section 11. Toxicological Information
    Routes of Entry        Absorbed through skin. Inhalation. Ingestion.    
    Toxicity to Animals        Acute oral toxicity (LD50): 1680 mg/kg [Mouse].    
    Chronic Effects on Humans        MUTAGENIC EFFECTS: Mutagenic for mammalian somatic cells. Mutagenic for bacteria and/or yeast.    
    DEVELOPMENTAL TOXICITY: Classified Reproductive system/toxin/female, Reproductive system/toxin/male,
    Development toxin [POSSIBLE].
    Other Toxic Effects on        Slightly hazardous in case of skin contact (irritant, permeator), of ingestion, of inhalation.    
    Humans
    Special Remarks on
    Not available.
    Toxicity to Animals
    Special Remarks on        May cause adverse reproductive effects (maternal effects on fertility -post-implantation, and fetotoxicity), and birth    
    Chronic Effects on Humans        defects.    
    May affect genetic material (mutagenic).
    Excreted in maternal milk in human.
    Special Remarks on other        Acute Potential Health Effects:    
    Toxic Effects on Humans        Skin: May cause skin irritation. It may be absorbed through the skin.    
    Eyes: Dust may cause eye irritation.
    Inhalation: Dust may cause respiratory tract irritation.
    Ingestion: May cause gastrointestinal tract irritation. May also affect behavior (toxic psychosis), metabolism
    (anorexia), and urinary system. This material is readily absorbed from the gastrointestinal tract. Ingestion of a
    massive single dose is unlikely to cause adverse effects.
    Chronic Potential Health Effects:
    Prolonged or repeated exposure by inhalation, ingestion, or skin contact may cause allergic reaction (possible
    hypersensitization).
    Other symptoms of chronic overdose effects may include, acne or other skin problems, weight loss or weight
    gain, hip or shoulder pain, fullness in face, fluid retention associated with sodium retention, potassium
    loss,swelling of feet or lower legs, excess or abnormal thirst, menstrual irregularities, nausea, vomiting, irregular
    heartbeat, muscle cramps, weakness, osteoporosis, increased susceptibility to infection, psychosis, and eye
    problems. May also affect urinary system (polyuria), liver, adrenal gland.
    Prednisolone

Section 12. Ecological Information
    Ecotoxicity        Not available.    
    BOD5 and COD        Not available.    
    Products of Biodegradation        Possibly hazardous short term degradation products are not likely. However, long term degradation products may    
    arise.
    The products of degradation are less toxic than the product itself.
    Toxicity of the Products
    of Biodegradation
    Special Remarks on the        Not available.    
    Products of Biodegradation

Section 13. Disposal Considerations
    Waste Disposal        Waste must be disposed of in accordance with federal, state and local environmental    
    control regulations.

Section 14. Transport Information
    DOT Classification        Not a DOT controlled material (United States).    
    Not applicable.
    Identification
    Not applicable.
    Special Provisions for
    Transport
    DOT (Pictograms)

Section 15. Other Regulatory Information and Pictograms
    New Jersey: Prednisolone
    Federal and State
    TSCA 8(b) inventory: Prednisolone
    Regulations
    California        California prop. 65: This product contains the following ingredients for which the State of California has found    
    Proposition 65        to cause cancer which would require a warning under the statute: No products were found.    
    Warnings
    California prop. 65: This product contains the following ingredients for which the State of California has found
    to cause birth defects which would require a warning under the statute: No products were found.
    Other Regulations        EINECS: This product is on the European Inventory of Existing Commercial Chemical Substances (EINECS No.    
    200-021-7).
    Canada: Listed on Canadian Domestic Substance List (DSL).
    China: Listed on National Inventory.
    Japan: Not listed on National Inventory (ENCS).
    Korea: Listed on National Inventory (KECI).
    Philippines: Listed on National Inventory (PICCS).
    Australia: Listed on AICS.
    CLASS D-2A: Material causing other toxic effects (VERY TOXIC).
    Other Classifications        WHMIS (Canada)    
    Class D-2B: Material causing other toxic effects (TOXIC).
    DSCL (EEC)        R62- Possible risk of impaired fertility.        S36- Wear suitable protective clothing.    
    R63- Possible risk of harm to the
    unborn child.
    Prednisolone
    Health Hazard
    HMIS (U.S.A.)        1 National Fire Protection    
    1 Flammability
    1 Association (U.S.A.)
    Fire Hazard
    1 0 Reactivity
    Health
    Reactivity
    0
    Specific hazard
    Personal Protection
    E
    WHMIS (Canada)
    (Pictograms)
    DSCL (Europe)
    (Pictograms)
    TDG (Canada)
    (Pictograms)
    ADR (Europe)
    (Pictograms)
    Protective Equipment
    Gloves.
    Lab coat.
    Dust respirator. Be sure to use an
    approved/certified respirator or
    equivalent.
    Safety glasses.


SECTION 16 - ADDITIONAL INFORMATION
N/A

泼尼松龙 分子结构与计算化学数据

分子结构数据

1、  摩尔折射率:95.48

2、  摩尔体积(cm3/mol):274.7

3、  等张比容(90.2K):766.8

4、  表面张力(dyne/cm):60.7

5、  极化率(10-24cm3):37.85

计算化学数据

1、   疏水参数计算参考值(XlogP):1.6

2、   氢键供体数量:3

3、   氢键受体数量:5

4、   可旋转化学键数量:2

5、   互变异构体数量:9

6、   拓扑分子极性表面积(TPSA):94.8

7、   重原子数量:26

8、   表面电荷:0

9、   复杂度:724

10、同位素原子数量:0

11、确定原子立构中心数量:7

12、不确定原子立构中心数量:0

13、确定化学键立构中心数量:0

14、不确定化学键立构中心数量:0

15、共价键单元数量:1

推荐供应商更多供应商>>

武汉共创科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99% 包装信息:1
联系方式:
联系人:罗 电话:18908446935 手机:18908446935

佛山信航生物科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99 包装信息:
联系方式:
联系人:刘 电话:17725670492 手机:17725670492

武汉联商网科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:医药级98% 包装信息:5KG/内膜袋
联系方式:
联系人:熊经理 电话:18872220794 手机:18872220794

大华伟业医药化工有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99 包装信息:1
联系方式:
联系人:宋先生 电话:02759212829 手机:15623424115

中山联久生物科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99% 包装信息:5KG/内膜袋
联系方式:
联系人:王彩 电话:18125350267 手机:18125350267

湖北鑫鸣泰化学有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99% 包装信息:100Kg,200Kg
联系方式:
联系人:黄 电话:027-50662354 手机:13264726139

湖北鑫鸣泰化学有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99% 包装信息:25kg/桶
联系方式:
联系人:刘经理 电话:027-51833411 手机:13237166274

上海源叶生物科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:HPLC≥98% 包装信息:100mg
联系方式:
联系人:陆建红 电话:86-21--67811725 手机:13817922965

佛山市嘉跃生物科技有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:医药级98% 包装信息:5KG/内膜袋 可拆
联系方式:
联系人:彭 电话:0731-85238073 手机:17373192935

湖北帝伯化工有限公司

产品介绍:
产品名称:泼尼松龙 Cas号:50-24-8 纯度:99 包装信息:1
联系方式:
联系人:王 电话:13829747784 手机:13829747784